Consent to the Distribution of New Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution inNew Zealand of the new medicines set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Zinc (as Zinc Sulphate heptahydrate) 1.0 mg, Copper (as Cupric Sulphate pentahydrate) 0.4 mg, Manganese (as Manganese Sulphate monohydrate) 0.1 mg, Chromium (as Chromic Chloride hexahydrate) 4 mcg, Selenium (as Selenious acid) 20 mcg, Iodide (as Sodium Iodide) 25 mcg, Molybdenum (as Ammonium molybdate tetrahydrate) 25 mcg per ml in 10 ml Solution for infusion Lyphomed Inc., Melrose Park, Illinois, United States of America MTE-7 Polyethylene glycol 4000 5.91% w/v, anhydrous sodium sulphate 0.57% w/v Powder for reconstitution (oral) Rice Steele & Company Limited, Tallaght, Dublin, Ireland Colocler Papaveretum 20 mg in 1 ml Solution for injection (ampoule) Astra Pharmaceuticals Pty Limited, North Ryde, New South Wales, Australia Papaveretum Injection Isofluorane 100% Volatile liquid for inhalation Rhone-Poulenc Chemicals Limited, Avonmouth, Bristol, England Isoflurane Inhalation Anaesthetic Capcipotriol hydrate 50 mcg per g in 30 gram and 100 gram Cream Leo Laboratories Limited, Dublin, Ireland Daivonex Monobasic sodium phosphate 16.1%, dibasic sodium phosphate 5.9% in 133 ml Enema C B Fleet & Co Inc., Lynchburg, Virginia, United States of America Fleet Enema Monobasic sodium phosphate 16.1%, dibasic sodium phosphate 5.9% in 66.6 ml Enema C B Fleet & Co Inc., Lynchburg, Virginia, United States of America Fleet Enema for Children Teicoplanin 100 mg, 200 mg, 400 mg Freeze dried powder for reconstitution for IV or IM injection Gruppo Lepetit S.p.A., Anagni (Frosinone), Italy Targocid Injection Nabumetone 500 mg Tablet Beecham Pharmaceuticals, Crawley, Sussex, England Relifex Interferon gamma-lb 100 mcg in 0.5 ml Solution for injection Genentech Inc., South San Francisco, California, United States of America Imukin Dated this 27th day of June 1994. C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.